SY-5609

DRUG2 trials

Sponsors

Syros Pharmaceuticals, Hoffmann-La Roche

Conditions

Advanced Solid TumorBreast CancerMetastatic Colorectal CancerPancreatic CancerSmall-cell Lung Cancer

Phase 1

A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

CompletedNCT04247126

Syros PharmaceuticalsAdvanced Solid Tumor, Breast Cancer, Pancreatic Cancer +1

Start: 2020-01-23End: 2023-03-30Updated: 2023-10-27

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

RecruitingNCT04929223

Hoffmann-La RocheMetastatic Colorectal Cancer

Start: 2021-10-22End: 2030-08-31Target: 542Updated: 2026-03-31

Related Papers

Phase I/Ib study of inavolisib (INAVO) + bevacizumab (BEV) or cetuximab (CETUX) for <i>PIK3CA</i> -mutated (mut) metastatic colorectal cancer (mCRC).

Journal of Clinical Oncology2026-01-10

Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

2023-12-0594 citations

Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax

Journal of Experimental & Clinical Cancer Research2023-07-2925 citations

Phase 1/1b study of SY-5609, a selective and potent CDK7 inhibitor, in advanced solid tumors and in 2L/3L pancreatic ductal adenocarcinoma (PDAC) in combination with gemcitabine +/- nab-paclitaxel.

Journal of Clinical Oncology2023-06-013 citations

Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).

Journal of Clinical Oncology2023-06-012 citations

Trial in progress: Phase I study of SY-5609, a potent, selective CDK7 inhibitor, with initial expansion in adults with metastatic pancreatic cancer.

Journal of Clinical Oncology2022-06-013 citations

SY5609, a Potent and Selective CDK7 Inhibitor, Potentiates BTK Inhibitor Activity in Mantle Cell Lymphoma Preclinical Models

Blood2021-11-054 citations

Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7

Journal of Medicinal Chemistry2021-11-0279 citations

CDK7 inhibitors as anticancer drugs.

2020-09-01146 citations

First-in-human phase I study of SY-5609, an oral, potent, and selective noncovalent CDK7 inhibitor, in adult patients with select advanced solid tumors.

Journal of Clinical Oncology2020-05-207 citations

Activity of SY-5609, an oral, noncovalent, potent, and selective CDK7 inhibitor, in preclinical models of colorectal cancer.

Journal of Clinical Oncology2020-05-203 citations